Report Content
Chapter 1 Methodology
1.1 Market definition
1.2 Base estimates & working
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Pulmonary arterial hypertension industry 3600 synopsis, 2016 - 2027
2.1.1 Business trends
2.1.2 Drug class trends
2.1.3 Route of administration trends
2.1.4 Regional trends
Chapter 3 Pulmonary Arterial Hypertension Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2016 – 2027 (USD Million)
3.3 Industry impact factors
3.3.1 Growth drivers
3.3.1.1 Increase in prevalence of pulmonary arterial hypertension
3.3.1.2 Strong product pipeline
3.3.1.3 Growing government initiatives
3.3.1.4 Rising global geriatric population
3.3.2 Industry pitfalls & challenges
3.3.2.1 Patent expiration
3.3.2.2 Side effects associated with the drugs
3.4 Growth potential analysis
3.4.1 By drug class
3.4.2 By route of administration
3.5 COVID-19 impact analysis
3.6 Porter’s analysis
3.7 Competitive landscape, 2020
3.7.1 Company matrix analysis, 2020
3.8 PESTEL analysis
Chapter 4 Pulmonary Arterial Hypertension Market, By Drug Class
4.1 Key segment trends
4.2 Prostacyclin and prostacyclin analogs
4.2.1 Market size, by region, 2016 – 2027 (USD Million)
4.3 Soluble guanylate cyclase (SGC) stimulators
4.3.1 Market size, by region, 2016 – 2027 (USD Million)
4.4 Endothelin receptor antagonist (ERA)
4.4.1 Market size, by region, 2016 - 2027 (USD Million)
4.5 Phosphodiesterase 5 (PDE-5)
4.5.1 Market size, by region, 2016 - 2027 (USD Million)
4.6 Vasodilators
4.6.1 Market size, by region, 2016 - 2027 (USD Million)
4.7 Others
4.7.1 Market size, by region, 2016 - 2027 (USD Million)
Chapter 5 Pulmonary Arterial Hypertension Market, By Drug Class
5.1 Key segment trends
5.2 Oral
5.2.1 Market size, by region, 2016 – 2027 (USD Million)
5.3 Intravenous
5.3.1 Market size, by region, 2016 – 2027 (USD Million)
5.4 Inhalation
5.4.1 Market size, by region, 2016 - 2027 (USD Million)
Chapter 6 Pulmonary Arterial Hypertension Market, By Region
6.1 Key regional trends
6.2 North America
6.2.1 Market size, by country, 2016 - 2027 (USD Million)
6.2.2 Market size, by drug class, 2016 - 2027 (USD Million)
6.2.3 Market size, by route of administration, 2016 – 2027 (USD Million)
6.2.4 U.S.
6.2.4.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.2.4.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.2.5 Canada
6.2.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.2.5.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.3 Europe
6.3.1 Market size, by country, 2016 - 2027 (USD Million)
6.3.2 Market size, by drug class, 2016 - 2027 (USD Million)
6.3.3 Market size, by route of administration, 2016 – 2027 (USD Million)
6.3.4 Germany
6.3.4.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.3.4.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.3.5 UK
6.3.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.3.5.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.3.6 France
6.3.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.3.6.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.3.7 Spain
6.3.7.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.3.7.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.3.8 Italy
6.3.8.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.3.8.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.4 Asia Pacific
6.4.1 Market size, by country, 2016 - 2027 (USD Million)
6.4.2 Market size, by drug class, 2016 - 2027 (USD Million)
6.4.3 Market size, by route of administration, 2016 – 2027 (USD Million)
6.4.4 Japan
6.4.4.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.4.4.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.4.5 China
6.4.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.4.5.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.4.6 India
6.4.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.4.6.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.4.7 Australia
6.4.7.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.4.7.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.4.8 South Korea
6.4.8.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.4.8.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.5 Latin America
6.5.1 Market size, by country, 2016 - 2027 (USD Million)
6.5.2 Market size, by drug class, 2016 - 2027 (USD Million)
6.5.3 Market size, by route of administration, 2016 – 2027 (USD Million)
6.5.4 Brazil
6.5.4.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.5.4.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.5.5 Mexico
6.5.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.5.5.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.5.6 Argentina
6.5.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.5.6.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.6 Middle East and Africa
6.6.1 Market size, by country, 2016 - 2027 (USD Million)
6.6.2 Market size, by drug class, 2016 - 2027 (USD Million)
6.6.3 Market size, by route of administration, 2016 – 2027 (USD Million)
6.6.4 South Africa
6.6.4.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.6.4.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.6.5 Saudi Arabia
6.6.5.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.6.5.2 Market size, by route of administration, 2016 – 2027 (USD Million)
6.6.6 UAE
6.6.6.1 Market size, by drug class, 2016 - 2027 (USD Million)
6.6.6.2 Market size, by route of administration, 2016 – 2027 (USD Million)
Chapter 7 Company Profiles
7.1 Competitive dashboard, 2020
7.2 Bayer AG
7.2.1 Business overview
7.2.2 Financial data
7.2.3 Product landscape
7.2.4 Strategic outlook
7.2.5 SWOT analysis
7.3 Eli Lilly and Company
7.3.1 Business overview
7.3.2 Financial data
7.3.3 Product landscape
7.3.4 Strategic outlook
7.3.5 SWOT analysis
7.4 Gilead Sciences, Inc.
7.4.1 Business overview
7.4.2 Financial data
7.4.3 Product landscape
7.4.4 Strategic outlook
7.4.5 SWOT analysis
7.5 GlaxoSmithKline plc.
7.5.1 Business overview
7.5.2 Financial data
7.5.3 Product landscape
7.5.4 Strategic outlook
7.5.5 SWOT analysis
7.6 Johnson & Johnson
7.6.1 Business overview
7.6.2 Financial data
7.6.3 Product landscape
7.6.4 Strategic outlook
7.6.5 SWOT analysis
7.7 Pfizer, Inc.
7.7.1 Business overview
7.7.2 Financial data
7.7.3 Product landscape
7.7.4 Strategic outlook
7.7.5 SWOT analysis
7.8 United Therapeutics Corporation
7.8.1 Business overview
7.8.2 Financial data
7.8.3 Product landscape
7.8.4 Strategic outlook
7.8.5 SWOT analysis
